Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid

American Journal of Hematology

Volumn 86, Issue 1, 2011, Pages 25-30

  Berenson, James R ^a,b,c   Yellin, Ori ^c   Crowley, John ^d   Makary, Adel ^e   Gravenor, Donald S ^f   Yang, Hank H ^g   Upadhyaya, Gargi H ^h   Flinn, Ian W ⁱ   Staszewski, Harry ^j   Tiffany, Natasha M ^k   Sanani, Shamel ^l   Farber, Charles M ^m   Morganstein, Neil ⁿ   Bolejack, Vanessa ^d   Nassir, Youram ^o   Hilger, James D ^b   Sefaradi, Ashkan ^c   Shamouelian, Albert ^c   Swift, Regina A ^c  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b Oncotherapeutics   (United States)

^c James R Berenson Inc   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e GEISINGER MEDICAL CENTER   (United States)

^f Family Cancer Center   (United States)

^g Oncology Care Medical Associates   (United States)

^h Whilshire Oncology Medical Group   (United States)

ⁱ Sarah Canon Research Institute and Tennessee Oncology   (United States)

^j WINTHROP UNIVERSITY HOSPITAL   (United States)

^k Hematology Oncology of Salem   (United States)

^l North Valley Hematology/Oncology Medical Group   (United States)

^m Carol G Simon Cancer Center   (United States)

ⁿ OVERLOOK HOSPITAL   (United States)

^o National Cancer Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; CORTICOSTEROID DERIVATIVE; CREATININE; LENALIDOMIDE; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; HEART INFARCTION; HUMAN; JAW OSTEONECROSIS; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK FACTOR; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; JAW DISEASES; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78650378301     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21912     Document Type: Article

References (56)

1. Kristinsson SY, Landgren O, Dickman PW, et al. Patterns of survival in multiple myeloma: A population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25: 1993-1999.
2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-2516.
3. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; l111: 2516-2520.
4. Greipp P, Leong T, Bennett J, et al. Plasmablastic morphology-an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group. Blood 1998; 7: 2501-2507.
5. Rajkumar S, Greipp P. Prognostic factors in multiple myeloma. Hematol Oncol Clin N Am 1999; 13: 1295-1314.
6. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
7. Durie B. Staging and kinetics of multiple myeloma. Semin Oncol 1986; 13: 300-309.
8. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression. Haematologica 2008; 93: 560-565.
9. Mundy GR, Bertoline DR. Bone destruction and hypercalcemia in plasma cell myeloma. Semin Oncol 1986; 13: 291-299.
10. Kyle RA. Multiple myeloma: Review of 869 cases. Mayo Clin Proc 1975; 50: 29-40.
11. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.
12. Berenson JR, Rosen LS, Howel A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200.
13. Woo SB, Hellstein JW, Kalmar JR. Systemic review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-761.
14. Saad F. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 2002; 1: 145-152.
15. Saad F. Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer 2005; 4: 31-37.
16. Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: From basic research to clinical evidence. Ann Oncol 2003; 14: 1468-1476.
17. Kunzmann V, Bauer E, Feurle J, et al. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384-392.
18. Mariani S, Muraro M, Pantaleoni F, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia 2005; 19: 664-670.
19. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
20. Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res 2005; 25: 144-151.
21. Berenson J, Shirina N, Chen YM, Dimopoulos M. Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels. J Clin Oncol ASCO Ann Meet Proc 2006; 24: 7505.
22. Avilés A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24: 227-230.
23. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99-102.
24. Morgan G, Davies F, Gregory W, et al. Evaluating the effects of zoledronic acid on overall survival in patients with multiple myeloma: Results of the Medical Research Council (MRC) myeloma IX study. J Clin Oncol 2010; 28 ( Suppl; abst 8021): 15s.
25. Van Poznak CH, Estilo CL, Sauter NP, et al. Osteonecrosis of the jaw in patients with metastatic breast cancer (abstract 3057). Breast Cancer Res Treat 2004; 88 ( Suppl 1): S131.
26. Hoff AO, Toth B, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (abstract 1218). J Bone Miner Res 2005; 20 ( Suppl 1): 555.
27. Van Poznak CH, Estilo CL. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology 2006; 20: 1053-1062.
28. Berenson JR, Yeh HS. The Van Poznak/Estilo article reviewed. Oncology 2006; 20: 1065-1066.
29. Khan AA, Sándor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36: 478-490.
30. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 100.
31. Khamaisi M, Regev E, Yarom N, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007; 92: 1172-1175.
32. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65-77.
33. Rajkumar SV, Hayman S, Gerts MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
34. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 2006; 134: 620-623.
35. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
36. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172.
37. Banerjee D, Asif A, Striker L, et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18.
38. Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289.
39. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349: 1676-1679.
40. Munier A, Grass V, Andrejak M, et al. Zoledronic acid and renal toxicity: Data from French adverse effect reporting database. Ann Pharm 2005; 39: 1194-1197.
41. Smetana S, Michlin A, Rosenman E, et al. Pamidronate-induced nephrotoxic tubular necrosis-A case report. Clin Nephrol 2004; 61: 63-67.
42. Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20: 1303-1317.
43. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842-854.
44. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc Ser B Stat Meth 1972; 34: 187-202.
45. Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer 2008; 113: 1588-1595.
46. Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma. Leukemia 2010; 24: 1043-1049.
47. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-1744.
48. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034.
49. Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
50. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [letter]. J Oral Maxillofac Surg 2003; 61: 1115-1118.
51. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
52. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61: 1104-1107.
53. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates (discussion). N Engl J Med 2005; 353: 99-102.
54. Ripamonti CI, Maniezzo M, Campa T, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumor patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20: 2009; 137-145.
55. Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008; 26: 5904-5909.
56. Sarasquete ME, García-Sanz R, Marín L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis. Blood 2008; 112: 2709-2712.